Roquefort Therapeutics PLC Director/PDMR Shareholding (2637R)
July 04 2022 - 11:57AM
UK Regulatory
TIDMROQ
RNS Number : 2637R
Roquefort Therapeutics PLC
04 July 2022
4 July 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Director/PDMR Shareholding
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech
company focused on early-stage opportunities in the biotechnology
sector, advises that Stephen West, Executive Chairman has purchased
ordinary shares in the Company in the market, as detailed
below:
Number of Ordinary Average Price Total Consideration
Name Shares Paid Per Share Paid
Stephen West 210,000 8.5159 pence GBP17,883.39
------------------- ---------------- --------------------
Following the above purchase of shares, Mr West holds interests
in the following Company securities:
Number of Ordinary % of Issued Share Number of Warrants
Name Shares Held Capital Held
Stephen West 5,049,123 7.02% 7,500,000
------------------- ------------------ -------------------
4,609,000 of Mr West's shares are held in the name of Cresthaven
Investments Pty Ltd ATF the Bellini Trust.
Enquiries:
Roquefort Therapeutics plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George
Beale
+44 (0)20 7466
Optiva Securities Limited (Broker) 5000
+44 (0)20 3411
Christian Dennis 1881
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech
company developing products through the pre-clinical phase prior to
partnering or selling to big pharma. The Company is a pre-clinical
biotech company focused on developing first in class Midkine
targeting drugs for the treatment of cancer.
Through extensive research resulting in validation through
publication in over 1,000 scientific journals, Roquefort
Therapeutics has identified the potential to exploit the broad
therapeutic potential of Midkine for a number of clinical
indications of unmet needs. Roquefort Therapeutics holds an
exclusive licence to the largest global IP portfolio on Midkine.
The Midkine blocking drug development markets have significant
global market potential (in the multi-billion dollars). Roquefort
Therapeutic's pre-clinical program is currently underway with an
initial focus on cancer.
This announcement contains inside information for the purposes
of Article 7 of the UK version of Market Regulation (EU) No
596/2014 on Market Abuse as it forms part of UK domestic law by
virtue of the European Union (Withdrawal) Act 2018, as amended ("UK
MAR").
The notification below, made in accordance with the requirements
of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Stephen West
------------------------------- ----------------------------------------
Reason for the notification
2
-------------------------------------------------------------------------
a) Position/status Executive Chairman
------------------------------- ----------------------------------------
b) Initial notification Initial
/Amendment
------------------------------- ----------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name Roquefort Therapeutics plc
------------------------------- ----------------------------------------
b) LEI 254900P4SISIWOR9RH34
------------------------------- ----------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------
a) Description of the Ordinary shares of GBP0.01 par value
financial instrument,
type of instrument ISIN: GB00BMDQ2T15
Identification code
------------------------------- ----------------------------------------
b) Nature of the transaction Purchase of 210,000 ordinary shares
------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
------------------------------- ---------------------------- ----------
8.5159 pence per share 210,000
----------------------------------------------------------------- ----------
d Aggregated information
- Aggregated volume * 210,000
- Price
* 8.5159p
------------------------------- ----------------------------------------
e) Date of the transactions 4 July 2022
------------------------------- ----------------------------------------
f) Place of the transactions London Stock Exchange (XLON); Main
Market
------------------------------- ----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBUGDRLUGDGDS
(END) Dow Jones Newswires
July 04, 2022 11:57 ET (15:57 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2024 to Jun 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2023 to Jun 2024
